Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14976 - 14997 of 14997 in total
GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
Matched Iupac: … hydroxypentylidene]amino}-1-hydroxypentylidene]amino}-1-hydroxyhexylidene]amino}-3-(C-hydroxycarbonimidoyl)propanoic acid
99mTc-glucarate(GLA) is an agent for non-invasive detection of breast tumours.
Investigational
Experimental
Experimental
Experimental
Doramapimod is a P38 MAP kinase inhibitor.
Investigational
Experimental
Experimental
Experimental
PA1050040, a second generation HIV-1 maturation inhibitor, is a chemical analog of Bevirimat (BVM). It inhibits virus replication by the same mechanism of action as BVM.
Investigational
VGV-1 is a potential salvage therapy for treatment of HIV infected people who have failed anti-retroviral therapy.
Investigational
Experimental
ANA971, an orally administered prodrug of isatoribine. Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection. ANA971 is a prodrug designed to improve the oral bioavailability of isatoribine. ANA971 resulted in higher levels of isatoribine in the blood than were present after...
Investigational
ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
Investigational
Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.
Investigational
AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.
Investigational
Displaying drugs 14976 - 14997 of 14997 in total